Should we screen for lung cancer? A 10-country analysis identifying key decision-making factors

Poon, Charlotte; Haderi, Artes; Roediger, Alexander; Yuan, Megan

doi:10.1016/j.healthpol.2022.06.003

Cited by 12 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lack of early stage diagnosis means most lung cancers are detected in advanced stages, often with distant metastasis not treatable with surgery. Chemotherapy and radiotherapy have more recently been complemented by targeted molecular therapies, such as tyrosine kinase inhibitors (TKIs) that have reshaped treatment, although resistance has developed in first and second generations [ 42 , 43 , 44 ]. The early performance with a rapid result turnaround of the next-generation sequencing technique (NGS) into routine laboratory practice would enable a better and wider selection of NSCLC patients for targeted therapies.…”

Section: Resultsmentioning

confidence: 99%

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices—such as population-level screening for lung cancer—are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

show abstract

Section: Resultsmentioning

confidence: 99%

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This is because, to the best of our knowledge, this is the first data collected on college students. Other countries besides Japan that have LCS programs include Canada, South Korea, Croatia, and the United States [15]. Within the limited available literature, willingness to undergo LCS in the United States ranged from 82.8% to 92.8% [35,36].…”

Section: Discussionmentioning

confidence: 99%

“…The LCS process varies across countries owing to varying evidence [14]. However, its effectiveness is often debated [15], with low screening rates observed among the target population [15] in countries where screening programs exist. Even in Japan, the LCS rate for those aged 40-79 is not high, at 53.4% for men and 45.6% for women [16].…”

Section: Introductionmentioning

confidence: 99%

Factors Influencing Willingness to Undergo Lung Cancer Screening in the Future: A Cross-Sectional Study of Japanese University Students

Mori,

Seguchi,

Iio

et al. 2024

Healthcare

View full text Add to dashboard Cite

Lung cancer (LC) is currently the leading cause of cancer deaths in Japan. Early detection through lung cancer screening (LCS) is important for reducing mortality. Therefore, exploring the factors affecting willingness to undergo LCS, particularly among young people, is important. This study aimed to elucidate the inclination toward LCS and its determining factors among Japanese university students. This cross-sectional study, involving 10,969 Japanese university students, was conducted in April 2023. A Pearson’s chi-square test and a binomial logistic regression analysis were used to analyze factors related to the dependent variable, willingness to undergo LCS in the future. Out of the 6779 participants (61.8%) involved in this study, 6504 (95.9%) provided valid responses, and 4609 (70.9%) expressed a willingness to undergo LCS in the future. Analysis revealed current smoking as a barrier to future willingness to undergo LCS. Other barriers included postponing the age of screening, anxiety about the screening content, and concerns about the possibility of having cancer after screening. Addressing barriers, such as current smoking and anxiety about screening, that prevent young people from undergoing LCS in the future is crucial. Therefore, universities should provide opportunities to educate students about LCS and explore various educational methods.

show abstract

“…At present, the treatment of NSCLC mainly includes surgery, chemotherapy, radiotherapy, molecular targeted therapy and immunotherapy [ 2 ]. Immune checkpoint antibodies specific for CTLA-4 and PD-L1/PD-1 have shown remarkable clinical success in several cancers, including NSCLC patients [ 3 ]. However, only 20–25% of treated patients respond to checkpoint inhibition therapy [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Trypanosoma cruzi-Derived Molecules Induce Anti-Tumour Protection by Favouring Both Innate and Adaptive Immune Responses

Freire

Landeira

Giacomini

et al. 2022

IJMS

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer mortality worldwide. Thus, the development of strategies against this type of cancer is of high value. Parasite infections can correlate with lower cancer incidence in humans and their use as vaccines has been recently explored in preclinical models. In this study, we investigated whether immunisations with a Trypanosoma cruzi lysate from epimastigotes protect from lung tumour growth in mice. We also explore the role of parasite glycans in the induction of the protective immune response. A pre-clinical murine cancer model using the lung tumour cell line LL/2 was used to evaluate the anti-tumour potential, both in preventive and therapeutic settings, of a T. cruzi epimastigote-derived protein lysate. Immunisation with the parasite lysate prevents tumour growth and induces both humoral and cellular anti-tumour immune responses to LL-2 cancer cells. The induced immunity and tumour protection were associated with the activation of natural killer (NK) cells, the production of interferon-γ (IFN-γ) and tumour cell cytotoxicity. We also show that mannose residues in the T. cruzi lysate induce Toll-like receptor (TLR) signalling. The evaluated T. cruzi lysate possesses anti-tumour properties likely by activating innate and adaptive immunity in a process where carbohydrates seem to be essential.

show abstract

Should we screen for lung cancer? A 10-country analysis identifying key decision-making factors

Cited by 12 publications

References 26 publications

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Factors Influencing Willingness to Undergo Lung Cancer Screening in the Future: A Cross-Sectional Study of Japanese University Students

Trypanosoma cruzi-Derived Molecules Induce Anti-Tumour Protection by Favouring Both Innate and Adaptive Immune Responses

Contact Info

Product

Resources

About